The NRG-RTOG 9601 study, coordinated at the ACR Center for Research and Innovation, finds that daily bicalutamide during and for 24 months after salvage radiation therapy improved long-term survival for men with persistent or recurrent cancer following radical prostatectomy. Read the press release.